Novel effects with polyethylene glycol modified pharmaceuticals
- 1 January 2002
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 28, 3-6
- https://doi.org/10.1016/s0305-7372(02)80002-0
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Clinical uses of pegylated pharmaceuticals in oncologyCancer Treatment Reviews, 2002
- Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving ChemotherapyJournal of Clinical Oncology, 2000
- Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable DrugsAnnals of Pharmacotherapy, 2000
- Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomesCancer, 1999
- A cytokinetic model describes the granulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteersClinical Pharmacology & Therapeutics, 1999
- Polyethylene glycol-conjugated pharmaceutical proteinsPharmaceutical Science & Technology Today, 1998
- Development of liposomal anthracyclines: from basics to clinical applications1This paper is based on a lecture presented at the 8th International Symposium on recent Advances in Drug Delivery Systems (Salt Lake City, UT, USA, 1997).1Journal of Controlled Release, 1998
- Polyethylene Glycol-Liposomal DoxorubicinDrugs, 1997
- Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinDrugs, 1997
- FilgrastimDrugs, 1994